As The American Journal of Managed Care^® (AJMC^®) Patient-Centered Oncology Care^® (PCOC) 2021 approaches, we thought you’d be interested in checking out some of the latest content from the editors.

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

https://www.ajmc.com/view/fda-panel-votes-to-keep-4-of-6-dangling-approvals-in-a-sign-of-things-to-come

Next-Generation Oncology APMs Need More Planning to Succeed

https://www.ajmc.com/view/next-generation-oncology-apms-need-more-planning-to-succeed

Real-World Evidence Is Key to Accelerating Oncology Approvals

https://www.ajmc.com/view/real-world-evidence-is-key-to-accelerating-oncology-approvals

Phase 2 Data for Tisagenlecleucel, Tafasitamab Show Objective Responses in More Than Half of Patients

https://www.ajmc.com/view/phase-2-data-for-tisagenlecleucel-tafasitamab-show-objective-responses-in-more-than-half-of-patients

Community-Based Initiative Doubles Accrual Rate of Black Participants in Cancer Trials

https://www.ajmc.com/view/community-based-initiative-doubles-accrual-rate-of-black-participants-in-cancer-trials

Camille Hertzka on Real-World Implications of Durvalumab, Increasing Diversity in Clinical Trials

https://www.ajmc.com/view/camille-hertzka-on-real-world-implications-of-durvalumab-minority-inclusion-in-clinical-trials

Enjoy!

Don’t forget to subscribe to our daily eNewsletter for live industry updates.

The AJMC^® team